Connect with us
Subscribe

Press Releases

Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine

Published

on

Companies will jointly develop BioNTech’s mRNA-based vaccine candidate BNT162 to prevent COVID-19 infection

Collaboration aims to accelerate global development of BNT162, leveraging expertise and resources of both companies.

Builds on 2018 agreement to jointly develop an mRNA-based influenza vaccine                        

United Arab Emirates, March 18, 2020 – Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the companies have agreed to a letter of intent regarding the co-development and distribution (excluding China) of a potential mRNA-based coronavirus vaccine aimed at preventing COVID-19 infection. The companies have executed a Material Transfer and Collaboration Agreement to enable the parties to immediately start working together. 

The collaboration aims to accelerate development of BioNTech’s potential first-in-class COVID-19 mRNA vaccine program, BNT162, which is expected to enter clinical testing by the end of April 2020. The rapid advancement of this collaboration builds on the research and development collaboration into which Pfizer and BioNTech entered in 2018 to develop mRNA-based vaccines for prevention of influenza. 

“We are proud that our ongoing, successful relationship with BioNTech gives our companies the resiliency to mobilize our collective resources with extraordinary speed in the face of this worldwide challenge,” said Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development & Medical, Pfizer. “We believe that by pairing Pfizer’s development, regulatory and commercial capabilities with BioNTech’s mRNA vaccine technology and expertise as one of the industry leaders, we are reinforcing our commitment to do everything we can to combat this escalating pandemic, as quickly as possible.” 

“This is a global pandemic, which requires a global effort. In joining forces with our partner Pfizer, we believe we can accelerate our effort to bring a COVID-19 vaccine to people around the world who need it,” said Ugur Sahin, Co-Founder and CEO of BioNTech.

The companies expect to utilize multiple research and development sites from both companies, including in the United States and Germany, to house the activities identified by the collaboration agreement.

The companies will begin collaborating immediately. They will finalize details of the agreement regarding financial terms, and all activities related to development, manufacturing and potential commercialization over the next few weeks. 

On March 13, 2020, Pfizer issued a five-point plan calling on the biopharmaceutical industry to join the company in committing to unprecedented collaboration to combat COVID-19.

About Pfizer: Breakthroughs That Change Patients’ Lives 

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer. 

Pfizer Disclosure Notice: 

The information contained in this release is as of March 17, 2020. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about Pfizer’s efforts to combat COVID-19, BioNTech’s potential COVID-19 mRNA vaccine, BNT162, a letter of intent regarding the co-development and co-commercialization (excluding China) by Pfizer and BioNTech of BNT162 and a Material Transfer and Collaboration Agreement, including their potential benefits, and the expected timing of a Phase 1 trial, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, whether and when a definitive agreement will be reached for the co-development and co-commercialization by Pfizer and BioNTech of BNT162 ; uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; whether and when any biologics license applications may be filed in any other jurisdictions for BNT162 or any other vaccine candidates under the collaboration; whether and when any such applications may be approved by regulatory authorities, which will depend on myriad factors, including making a determination as to whether the product’s benefits outweigh its known risks and determination of the product’s efficacy and, if approved, whether BNT162 will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of BNT162; uncertainties regarding the ability to obtain recommendations from vaccine technical committees and other public health authorities regarding BNT162 and uncertainties regarding the commercial impact of any such recommendations; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results”, as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

About BioNTech

Biopharmaceutical New Technologies (BioNTech) is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.  The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Eli Lilly and Company, Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Genevant, Fosun, and Pfizer.  For more information, please visit www.BioNTech.de.

Forward-looking statement

This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, the ability of BioNTech to develop and commercialize a vaccine for COVID-19, BioNTech’s potential COVID-19 mRNA vaccine, BNT162, a letter of intent regarding the co-development and co-commercialization (excluding China) by Pfizer and BionNTech of BNT162 and a Material Transfer and Collaboration Agreement, including their potential benefits, and the expected timing of a Phase 1 trial of BNT162. Any forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events, and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: competition to create a vaccine for Covid-19 and potential difficulties. For a discussion of these and other risks and uncertainties, see the section entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in BioNTech’s Registration Statement on Form F-1 filed with the SEC on September 9, 2019, as amended, which has been filed with the SEC and is available on the SEC’s website at www.sec.gov. All information in this press release is as of the date of the release, and BioNTech undertakes no duty to update this information unless required by law.

Contact:

Media Relations

Anand George Zachariah

+971 4 330 4010 ext.455 or +971 55 3766809

anandgeorge.zachariah@fleishmaneurope.com

Continue Reading
Click to comment

Magazine

HRCI Assumes ISO International Secretariat Role for Technical Committee 260 on Human Resource Management

Published

on

May 04, 2021 07:00 ET | Source: HRCI

ALEXANDRIA, Va., May 04, 2021 (GLOBE NEWSWIRE) — HRCI®, the premier HR credentialing and learning organization, is honored to announce that the American National Standards Institute (ANSI) has appointed HRCI as the International Secretariat for the International Organization for Standardization (ISO) Technical Committee (TC) 260 on Human Resource Management. ANSI is the U.S. member body to the ISO.

ISO TC 260, formed in 2011, is responsible for the development of a series of standards for human resource management processes and practices. There are 19 standards and technical specifications published, with 13 more under development. One of the most noteworthy standards from this work is ISO 30414, Human Capital Reporting, which many Chief Financial Officer’s believe is a safe harbor for the recent ruling from the SEC requiring Human Capital Management Disclosures. The forthcoming ISO 301415 standard will also be an important standard for organizations, helping them create a culture of Diversity and Inclusion.

HRCI looks forward to providing effective leadership and continuing the development of additional standards to guide and optimize organizational performance, value creation, sustainable development and workforce productivity/satisfaction/engagement.

“In keeping with HRCI’s role as the global leader in certification programs, we are excited to be selected as the ISO Technical Committee on Human Resource Management. Leading this initiative to develop standards and practices for global human resources management is a natural expansion of HRCI’s responsibilities to the HR community,” said Dr. Amy Dufrane, SPHR, CAE, HRCI Chief Executive Officer.

“We are proud that HRCI is at the helm of standardization efforts that focus on human resources, which is often a vital factor in an organization’s success,” said S. Joe Bhatia, ANSI president and CEO. “We are excited to see additional progress unfold that will protect and support the interests and vitality of companies, and their employees, on a global scale.”

About HRCI®

HRCI®, headquartered in Alexandria, Virginia, is the premier credentialing and learning organization for the human resources profession. For over 45 years, we have set the global standard for HR expertise and excellence through our commitment to the development and advancement of businesspeople in the people business. HRCI develops and offers world-class learning, as well as the administration of eight global certifications and is dedicated to helping professionals achieve new competencies that drive business results. Learn more at www.hrci.org.

About ANSI
The American National Standards Institute (ANSI) is a private non-profit organization whose mission is to enhance both the global competitiveness of U.S. business and the U.S. quality of life by promoting and facilitating voluntary consensus standards and conformity assessment systems, and safeguarding their integrity. Its membership is comprised of businesses, professional societies and trade associations, standards developers, government agencies, and consumer and labor organizations. The Institute represents and serves the diverse interests of more than 270,000 companies and organizations and 30 million professionals worldwide. ANSI is the official U.S. representative to the International Organization for Standardization (ISO) and, via the U.S. National Committee, the International Electrotechnical Commission (IEC). For more information, visit www.ansi.org.

About ISO
ISO is an independent, non-governmental international organization with a membership of 165 national standards bodies through its members, it brings together experts to share knowledge and develop voluntary, consensus-based, market-relevant International Standards that support innovation and provide solutions to global challenges. The Central Secretariat in located in Geneva, Switzerland. Learn more about our structure and how we are governed.

ISO is the Organization for International Standards. It is a non-governmental global entity founded in 1947 and is comprised of 165 countries who come together through National standards bodies to develop proprietary, industry, and commercial global standards. The most recognizable and noteworthy series of standards is ISO 9001 Quality Management.
www.iso.org

https://www.globenewswire.com/news-release/2021/05/04/2222124/0/en/HRCI-Assumes-ISO-International-Secretariat-Role-for-Technical-Committee-260-on-Human-Resource-Management.html

Continue Reading

Press Releases

The Arab Academy for Science, Technology and Maritime Transport becomes an Approved Provider from the HRCI through the Community Service Program(Cairo Branch)

Published

on

Press Release

Cairo, 10th April 2021

The Arab Academy for Science Technology and Maritime Transport (AASTMT), held a live webinar on the 10th of April 2021 to announce the pleasure of becoming an Approved Provider from the HR Certification Institute, headquartered in Virginia, USA. through the Community Service Programs and Continuing Education (Cairo Branch)

The HRCI is the premier credentialing and learning organization for the human resources profession.

The Community Service Programs and Continuing Education (Cairo Branch) has clarified to the attendees during the live webinar the difference between the different certification exams provided by the HRCI, the eligibility requirements, the fees, the curriculum content, and the exam length & Format.

The Continuing Education program highlighted the advantages of the certification for HR professionals; HRCI certification holders report better employment prospects, higher annual salaries, faster income growth, and higher levels of career satisfaction.

Today, HR professionals from over 100 countries proudly maintain the HR Certification Institute’s credentials as a mark of world-class HR aptitude and innovation.

Moreover, the Continuing Education program announced to be offering different courses in the HR domain whose training hours would be officially certified from the HRCI, aiming to enhance HR professionals’ capabilities and technical skills in the HR field; including for example:

Advanced Compensation Management, Advanced Performance Management, KPIs Implementation, Competency-Based Interviews, HR Policies & Procedures Development, HR Analytics & Business Intelligence, Workplace Investigations, and others.

The live webinar was headed by Dr. Nevine Karam The Director of Continuing Education Program and was presented by Ms. Mariham Magdy (Certified International Professional in HR from the HRCI, Professional Certified Trainer from the American University in Cairo, The Arab Trainers Union & The Council of Arab Economic Unity)

A precious commentary was done by Prof. Ghada El-Kot (Deputy President for Strategic Affairs and Professor of HR and OB) by the end of the webinar to raise the awareness of HR professionals about the importance of acquiring the necessary HR knowledge before starting their professional careers in the HR field. In addition to the necessity of enriching such knowledge every now and then to build capably their careers in this critical field.

Please Follow the Link to the recorded webinar:

https://fb.watch/56H_erQh0T/

Continue Reading

Press Releases

Grand Stevie® Award Winners Announced in the 2021 Middle East & North Africa Stevie Awards

Published

on

·         DP DHL and UAE Ministry of Health and Prevention win top Stevie Awards

·         Grand Stevie winners to be honored at a virtual award ceremony on 2 June

The Stevie® Awards have announced the Grand Stevie Award winners in the second annual Middle East & North Africa Stevie Awards. The winners will be honored during a virtual award ceremony on 2 June.

The Middle East & North Africa Stevie Awards, sponsored by the Ras Al Khaimah Chamber of Commerce & Industry, is an international business awards competition open to all organizations in 17 nations in the Middle East and North Africa. The focus of the awards is recognizing innovation in all its forms. 

This year more than 400 nominations were considered in the judging process by more than 70 professionals, whose average ratings determined the Gold, Silver, and Bronze Stevie Award winners announced last month. For a complete list of the 2021 Stevie Award winners, visit https://MENA.StevieAwards.com.

In addition to the Gold, Silver, and Bronze Stevie Awards, the top winner overall (total number of points conferred by total Gold, Silver, and Bronze Stevie wins) and the highest-scoring nominations are awarded the Grand Stevie Awards.

The Two Grand Stevie Award Winners are:

ORGANIZATION OF THE YEAR: DP DHL: which earned 26.5 award points for the achievements of their affiliates in Jordan, Lebanon, Qatar, Saudi Arabia and the United Arab Emirates.  The Germany-headquartered global logistics and transportation company is no stranger to the top honor in Stevie Awards competitions, having won numerous Organization of the Year honors in the German Stevie Awards, the Stevie Awards for Sales & Customer Service, and other Stevie Awards programs.

HIGHEST-RATED NOMINATION OF THE YEAR: The “Stroke Golden Hour” nomination submitted by the UAE Ministry of Health and Prevention, in Dubai, received the highest average score from the judges (9.17 out of 10) in this year’s competition.  The Gold Stevie winner for Excellence in Innovation in Government – Organizations with 100 or More Employees, the nomination describes the development of an IT solution that almost halved the “door to needle” treatment time for stroke victims at MOHAP facilities.  One judge commented on the nomination, “A perfect example of an IT solution supporting a noble cause: reducing mortality and morbidity due to stroke. Using modern technologies like VR to assist patients is another welcome move.”

Stevie Award winners will be celebrated at a virtual awards ceremony on 2 June.  Registration for the ceremony is ongoing.

“We are thrilled to announce the 2021 Grand Stevie Award winners. DP DHL and the UAE Ministry of Health and Prevention have proven to be exceptional in the eyes of Stevie Award judges around the globe,” said Maggie Gallagher, President of the Stevie Awards.

Complete information about the virtual awards ceremony is available at https://stevieawards.com/mena/tickets

The virtual ceremony will feature digital versions of all of the things that people love about Stevie Awards events, including networking, acceptance speeches, red carpet photographs, and red-carpet interviews. 

If you, as a representative of the press, are interested in participating in the virtual award ceremony of the Middle East & North Africa Stevie Awards on 2 June at 14 GST., please contact us at help+MENA@stevieawards.com.

The third edition of the Middle East & North Africa Stevie Awards will open for entries in September 2021.

 ———————————————————

About the Stevie® Awards

Stevie Awards are conferred in eight programs: the Asia-Pacific Stevie Awards, the German Stevie Awards, The American Business Awards®, The International Business Awards®, the Middle East & North Africa Stevie Awards, the Stevie Awards for Women in Business, the Stevie Awards for Great Employers, and the Stevie Awards for Sales & Customer Service. Stevie Awards competitions receive more than 12,000 nominations each year from organizations in more than 70 nations. Honoring organizations of all types and sizes and the people behind them, the Stevies recognize outstanding performances in the workplace worldwide. Learn more about the Stevie Awards at www.StevieAwards.com

Continue Reading

HRCI

HRCI

Recent Posts

Articles5 days ago

How did the International Certification from the HRCI change your career?

Testimonials from Certified HR Professionals in the Middle East Journalism: Menna Hamdy Mostafa Gallal (PHRi, Egypt) – Recruitment Manager at...

Magazine6 days ago

HRCI Assumes ISO International Secretariat Role for Technical Committee 260 on Human Resource Management

May 04, 2021 07:00 ET | Source: HRCI ALEXANDRIA, Va., May 04, 2021 (GLOBE NEWSWIRE) — HRCI®, the premier HR credentialing and...

Magazine6 days ago

Interview with Eureka (ICS Learn Student) Customer Service Agent – Qatar Airways

Interviewer: Mariham Magdy 1. HR Revolution Middle East: Welcome to HR Revolution Middle East Magazine. It’s a great pleasure to...

Press Releases2 weeks ago

The Arab Academy for Science, Technology and Maritime Transport becomes an Approved Provider from the HRCI through the Community Service Program(Cairo Branch)

Press Release Cairo, 10th April 2021 The Arab Academy for Science Technology and Maritime Transport (AASTMT), held a live webinar...

Articles3 weeks ago

تعاون بين شباب السودان ومصر لتنظيم النسخة الثامنة لتيدكس ودمدني بالسودان

شباب من مصر والسودان يترجموا التعاون بين البلدين الشقيقين في المشاركة في تنظيم النسخة الثامنة لمؤتمر تيدكس ودمدني بالسودان. يعتبر...

Press Releases4 weeks ago

Grand Stevie® Award Winners Announced in the 2021 Middle East & North Africa Stevie Awards

·         DP DHL and UAE Ministry of Health and Prevention win top Stevie Awards ·         Grand Stevie winners to be...

Articles1 month ago

الأكاديمية العربية تقوم بتكريم منظمي تيدكس بجمهورية السودان

مع حرص الأكاديمية العربية للعلوم والتكنولوجيا والنقل البحري لنشر العلم والتطوير في شتى الدول العربية والأفريقية وإتساقاً مع استراتيجية وسياسة...

Press Releases2 months ago

Winners in the 2021 Middle East & North Africa Stevie® Awards Announced

Honors Sponsored by the RAK Chamber of Commerce & Industry Recognize Innovation in 17 MENA Nations Winners in the second...

Interviews2 months ago

Interview with Mustafa Naisah, Mustafa Naisah, People Learning & Growth Partner

“We need to tap into the mind-set and enhance it by changing the story we tell ourselves each morning and...

Articles2 months ago

Wellbeing @ Work Summit Middle East 2021 – Diversity, Inclusion and the Holistic Wellbeing approach

Written by: Cinzia Nitti A working environment characterized by greater Diversity & Inclusion has more chance of being a place...

ICS Learn

ICS Learn

Categories

Trending

Hrrevolution News

Subscribe to our weekly newsletter below and never miss the latest News.